US20090257994A1
(en)
*
|
2001-04-30 |
2009-10-15 |
City Of Hope |
Chimeric immunoreceptor useful in treating human cancers
|
US11278594B2
(en)
|
2001-04-30 |
2022-03-22 |
City Of Hope |
Chimeric immunoreceptor useful in treating human cancers
|
US7994298B2
(en)
|
2004-09-24 |
2011-08-09 |
Trustees Of Dartmouth College |
Chimeric NK receptor and methods for treating cancer
|
US9273283B2
(en)
|
2009-10-29 |
2016-03-01 |
The Trustees Of Dartmouth College |
Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
|
US9181527B2
(en)
|
2009-10-29 |
2015-11-10 |
The Trustees Of Dartmouth College |
T cell receptor-deficient T cell compositions
|
WO2011130491A2
(en)
|
2010-04-14 |
2011-10-20 |
Roger Williams Medical Center |
Methods and compositions for treating hiv
|
CA2816379A1
(en)
*
|
2010-10-27 |
2012-05-03 |
Baylor College Of Medicine |
Chimeric cd27 receptors for redirecting t cells to cd70-positive malignancies
|
KR102062407B1
(ko)
*
|
2010-12-09 |
2020-01-03 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
암을 치료하기 위한 키메릭 항원 수용체 변형 t 세포의 용도
|
WO2012082946A2
(en)
*
|
2010-12-14 |
2012-06-21 |
The Regents Of The University Of California |
Creation of super-stable coie1 plasmids by duplication of sl 1-4 sequence and point mutations.
|
AU2011343887B2
(en)
*
|
2010-12-14 |
2016-06-16 |
University Of Maryland, Baltimore |
Universal anti-tag chimeric antigen receptor-expressing T cells and methods of treating cancer
|
SG192010A1
(en)
|
2011-01-18 |
2013-08-30 |
Univ Pennsylvania |
Compositions and methods for treating cancer
|
BR112013024395B1
(pt)
|
2011-03-23 |
2021-10-26 |
Fred Hutchinson Cancer Research Center |
Composições adotivas de imunoterapia celular e método para fabricação da dita composição
|
EP2694549B1
(en)
*
|
2011-04-08 |
2018-08-15 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer
|
GB201108236D0
(en)
*
|
2011-05-17 |
2011-06-29 |
Ucl Business Plc |
Method
|
ES2723181T3
(es)
|
2011-07-29 |
2019-08-22 |
Univ Pennsylvania |
Receptores de conmutación coestimulante
|
US9833476B2
(en)
|
2011-08-31 |
2017-12-05 |
The Trustees Of Dartmouth College |
NKP30 receptor targeted therapeutics
|
EP3692794A1
(en)
*
|
2011-09-16 |
2020-08-12 |
Baylor College of Medicine |
Targeting the tumor microenvironment using manipulated nkt cells
|
WO2013040557A2
(en)
|
2011-09-16 |
2013-03-21 |
The Trustees Of The University Of Pennsylvania |
Rna engineered t cells for the treatment of cancer
|
ES2861435T3
(es)
*
|
2011-11-03 |
2021-10-06 |
Univ Pennsylvania |
Composiciones específicas de B7-H4 aisladas y métodos de uso de las mismas
|
CN104159909A
(zh)
|
2012-02-22 |
2014-11-19 |
宾夕法尼亚大学董事会 |
产生用于癌症治疗的t细胞持续性群体的组合物和方法
|
WO2013126733A1
(en)
|
2012-02-22 |
2013-08-29 |
The Trustees Of University Of Pennsylvania |
Use of icos-based cars to enhance antitumor activity and car persistence
|
JP2015509716A
(ja)
|
2012-02-22 |
2015-04-02 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
第二世代キメラ抗原受容体におけるcd2シグナル伝達ドメインの使用
|
WO2013126720A2
(en)
*
|
2012-02-22 |
2013-08-29 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for the assessment of target cancer cell resistance to car engineered t cell killing
|
CA2869562C
(en)
*
|
2012-04-11 |
2023-09-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric antigen receptors targeting b-cell maturation antigen
|
EP3505537A1
(en)
|
2012-05-07 |
2019-07-03 |
Trustees of Dartmouth College |
Anti-b7-h6 antibody, fusion proteins, and methods of using the same
|
US9844582B2
(en)
|
2012-05-22 |
2017-12-19 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
|
EP3964567A1
(en)
|
2012-05-25 |
2022-03-09 |
Cellectis |
Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
|
CN103483452B
(zh)
*
|
2012-06-12 |
2021-08-13 |
上海细胞治疗集团有限公司 |
双信号独立的嵌合抗原受体及其用途
|
ES2733525T3
(es)
*
|
2012-07-13 |
2019-11-29 |
Univ Pennsylvania |
Métodos para evaluar la adecuación de los linfocitos T transducidos para su administración
|
AU2013305838A1
(en)
*
|
2012-08-20 |
2015-02-26 |
Fred Hutchinson Cancer Center |
Method and compositions for cellular immunotherapy
|
AU2013204922B2
(en)
|
2012-12-20 |
2015-05-14 |
Celgene Corporation |
Chimeric antigen receptors
|
US9573988B2
(en)
|
2013-02-20 |
2017-02-21 |
Novartis Ag |
Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
|
PT2958943T
(pt)
*
|
2013-02-20 |
2019-12-17 |
Novartis Ag |
Tratamento do cancro usando recetor de antigénios quiméricos anti-egfrviii humanizados
|
JP2016510594A
(ja)
|
2013-03-05 |
2016-04-11 |
ベイラー カレッジ オブ メディスンBaylor College Of Medicine |
Tリンパ球におけるヘパラナーゼの発現
|
AU2014236726A1
(en)
*
|
2013-03-14 |
2015-09-17 |
Bellicum Pharmaceuticals, Inc. |
Methods for controlling T cell proliferation
|
US9657105B2
(en)
*
|
2013-03-15 |
2017-05-23 |
City Of Hope |
CD123-specific chimeric antigen receptor redirected T cells and methods of their use
|
EP2970426B1
(en)
|
2013-03-15 |
2019-08-28 |
Michael C. Milone |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
AU2014240083C1
(en)
|
2013-03-15 |
2019-10-24 |
Celgene Corporation |
Modified T lymphocytes
|
TWI654206B
(zh)
|
2013-03-16 |
2019-03-21 |
諾華公司 |
使用人類化抗-cd19嵌合抗原受體治療癌症
|
CN107460201A
(zh)
*
|
2013-05-08 |
2017-12-12 |
科济生物医药(上海)有限公司 |
编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞
|
WO2014183066A2
(en)
|
2013-05-10 |
2014-11-13 |
Whitehead Institute For Biomedical Research |
Protein modification of living cells using sortase
|
US11077144B2
(en)
|
2013-05-13 |
2021-08-03 |
Cellectis |
CD19 specific chimeric antigen receptor and uses thereof
|
KR102248157B1
(ko)
*
|
2013-05-13 |
2021-05-03 |
셀렉티스 |
Cd19 특이적 키메라 항원 수용체 및 이의 용도
|
RU2555533C9
(ru)
*
|
2013-05-23 |
2016-03-10 |
Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) |
Рекомбинантная плазмидная днк, кодирующая химерное антитело против фактора некроза опухоли-альфа человека, линия эукариотических клеток-продуцент химерного антитела и способ получения химерного антитела
|
WO2014201378A1
(en)
*
|
2013-06-13 |
2014-12-18 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with extended-pk il -2 and adoptive cell therapy
|
AU2014348657A1
(en)
*
|
2013-11-13 |
2016-05-19 |
Novartis Ag |
mTOR inhibitors for enhancing the immune response
|
CA3225453A1
(en)
|
2013-12-19 |
2015-06-25 |
Novartis Ag |
Human mesothelin chimeric antigen receptors and uses thereof
|
AU2014368383B2
(en)
*
|
2013-12-20 |
2020-01-16 |
Cellectis |
Method of engineering multi-input signal sensitive T cell for immunotherapy
|
JP6793902B2
(ja)
|
2013-12-20 |
2020-12-02 |
ノバルティス アーゲー |
調節可能キメラ抗原受容体
|
EP4303229A3
(en)
|
2014-01-21 |
2024-04-17 |
Novartis AG |
Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
|
EP3104866A4
(en)
|
2014-02-14 |
2017-08-02 |
Bellicum Pharmaceuticals, Inc. |
Methods for activating t cells using an inducible chimeric polypeptide
|
TW202214691A
(zh)
|
2014-03-21 |
2022-04-16 |
美商艾伯維有限公司 |
抗-egfr抗體及抗體藥物結合物
|
IL293603B2
(en)
|
2014-04-07 |
2024-03-01 |
Novartis Ag |
Cancer treatment using chimeric antigen receptor (CAR) against CD19
|
CA2945305C
(en)
|
2014-04-10 |
2023-10-17 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Method and compositions for cellular immunotherapy
|
JP2017514471A
(ja)
*
|
2014-04-23 |
2017-06-08 |
ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム |
キメラ抗原受容体(car)並びにその製造及び使用方法
|
DK3143134T3
(da)
|
2014-05-15 |
2021-01-04 |
Nat Univ Singapore |
Modificerede, naturlige dræberceller og anvendelser deraf
|
ES2846811T3
(es)
|
2014-06-06 |
2021-07-29 |
Bluebird Bio Inc |
Composiciones de células T mejoradas
|
TWI718992B
(zh)
|
2014-07-21 |
2021-02-21 |
瑞士商諾華公司 |
使用cll-1嵌合抗原受體治療癌症
|
CN106687483B
(zh)
|
2014-07-21 |
2020-12-04 |
诺华股份有限公司 |
使用人源化抗-bcma嵌合抗原受体治疗癌症
|
CN112481283A
(zh)
|
2014-07-21 |
2021-03-12 |
诺华股份有限公司 |
使用cd33嵌合抗原受体治疗癌症
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
MY189028A
(en)
|
2014-08-19 |
2022-01-20 |
Novartis Ag |
Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
|
US11111288B2
(en)
|
2014-08-28 |
2021-09-07 |
Bioatla, Inc. |
Conditionally active chimeric antigen receptors for modified t-cells
|
TWI751102B
(zh)
|
2014-08-28 |
2022-01-01 |
美商奇諾治療有限公司 |
對cd19具專一性之抗體及嵌合抗原受體
|
AU2015308818B2
(en)
*
|
2014-08-28 |
2021-02-25 |
Bioatla Llc |
Conditionally active chimeric antigen receptors for modified T-cells
|
US10888608B2
(en)
|
2014-09-02 |
2021-01-12 |
Bellicum Pharmaceuticals, Inc. |
Costimulation of chimeric antigen receptors by MyD88 and CD40 polypeptides
|
CN107074969A
(zh)
*
|
2014-09-09 |
2017-08-18 |
优努姆治疗公司 |
嵌合受体及其在免疫治疗中的应用
|
DK3194443T3
(da)
|
2014-09-17 |
2021-09-27 |
Novartis Ag |
Målretning af cytotoksiske celler med kimære receptorer i forbindelse med adoptiv immunterapi
|
BR112017005631A2
(pt)
*
|
2014-09-19 |
2018-06-26 |
City Of Hope |
células t com receptor de antígeno coestimulador quimérico direcionadas à il13ra2
|
SG11201702895SA
(en)
|
2014-10-08 |
2017-05-30 |
Novartis Ag |
Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
|
MA41538A
(fr)
|
2014-10-17 |
2017-12-26 |
Baylor College Medicine |
Cellules immunitaires bipartites et tripartites de signalisation
|
ES2879612T3
(es)
|
2014-10-20 |
2021-11-22 |
Juno Therapeutics Inc |
Métodos y composiciones para dosificación en terapia celular adoptiva
|
US9650428B2
(en)
*
|
2014-12-02 |
2017-05-16 |
Roger Williams Hospital |
Methods and compositions for treating cancer
|
MX2017007138A
(es)
|
2014-12-03 |
2017-08-28 |
Juno Therapeutics Inc |
Metodos y composiciones para terapia celular adoptiva.
|
SI3628687T1
(sl)
|
2014-12-12 |
2021-12-31 |
2Seventy Bio, Inc. |
BCMA himerni antigenski receptorji
|
EP3556768A1
(en)
|
2014-12-24 |
2019-10-23 |
Aadigen, LLC |
Peptides and nanoparticles for intracellular delivery of molecules
|
KR20170093254A
(ko)
|
2014-12-29 |
2017-08-14 |
노파르티스 아게 |
키메라 항원 수용체-발현 세포를 제조하는 방법
|
WO2016115482A1
(en)
|
2015-01-16 |
2016-07-21 |
Novartis Pharma Ag |
Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor
|
JP7264592B2
(ja)
|
2015-01-26 |
2023-04-25 |
ザ ユニバーシティー オブ シカゴ |
IL13Rα2結合剤及び癌治療におけるその使用
|
JP6912386B2
(ja)
*
|
2015-01-26 |
2021-08-04 |
ザ ユニバーシティー オブ シカゴ |
癌特異的なIL13Rα2を認識するCAR T細胞
|
MX2017009181A
(es)
|
2015-01-26 |
2017-11-22 |
Cellectis |
Receptores de antigenos quimericos de cadena sencilla especificos de anti-cll1 para inmunoterapia de cancer.
|
MA41433A
(fr)
*
|
2015-01-26 |
2017-12-05 |
Baylor College Medicine |
Cellules immunitaires universelles pour l'immunothérapie anticancéreuse
|
JP6886404B2
(ja)
|
2015-01-30 |
2021-06-16 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California |
初代造血細胞におけるタンパク質送達
|
WO2016126608A1
(en)
|
2015-02-02 |
2016-08-11 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
US10557140B2
(en)
|
2015-02-02 |
2020-02-11 |
Industry-Academic Cooperation Foundation, Dankook University |
CTLA-4-targeting trans-splicing ribozyme for delivery of chimeric antigen receptor, and use thereof
|
US20160228547A1
(en)
*
|
2015-02-06 |
2016-08-11 |
Batu Biologics, Inc. |
Chimeric antigen receptor targeting of tumor endothelium
|
CA2981142A1
(en)
|
2015-03-27 |
2016-10-06 |
University Of Southern California |
Car t-cell therapy directed to lhr for the treatment of solid tumors
|
JP6879932B2
(ja)
|
2015-04-06 |
2021-06-02 |
サイトイミューン セラピューティクス, インコーポレイテッドCytoimmune Therapeutics, Llc |
神経膠芽腫のためのegfr指向car療法
|
SI3280729T1
(sl)
|
2015-04-08 |
2022-09-30 |
Novartis Ag |
Terapije CD20, terapije CD22 in kombinacija terapij s celico, ki izraža himerni antigenski receptor CD19 (CAR)
|
JP7114457B2
(ja)
|
2015-04-17 |
2022-08-08 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
キメラ抗原受容体発現細胞の有効性および増殖を改善するための方法
|
WO2016176652A2
(en)
|
2015-04-29 |
2016-11-03 |
Fred Hutchinson Cancer Research Center |
Modified stem cells and uses thereof
|
CN107995913B
(zh)
|
2015-05-18 |
2022-02-11 |
T细胞受体治疗公司 |
使用融合蛋白对tcr重编程的组合物和方法
|
WO2016185443A1
(en)
|
2015-05-20 |
2016-11-24 |
Novartis Ag |
Pharmaceutical combination of everolimus with dactolisib
|
WO2016185035A1
(en)
*
|
2015-05-20 |
2016-11-24 |
Cellectis |
Anti-gd3 specific chimeric antigen receptors for cancer immunotherapy
|
US20180161369A1
(en)
|
2015-05-29 |
2018-06-14 |
Fred Hutchinson Cancer Research Center |
Compositions for cellular immunotherapy
|
EP3302559B1
(en)
|
2015-06-04 |
2022-01-12 |
University of Southern California |
Lym-1 and lym-2 targeted car cell immunotherapy
|
AR105433A1
(es)
|
2015-07-21 |
2017-10-04 |
Novartis Ag |
Métodos para mejorar la eficacia y expansión de las células inmunes
|
WO2017023803A1
(en)
|
2015-07-31 |
2017-02-09 |
Regents Of The University Of Minnesota |
Modified cells and methods of therapy
|
JP6751493B2
(ja)
*
|
2015-08-05 |
2020-09-09 |
セルレブメド インコーポレーテッド |
キメラ抗原受容体及びキメラ抗原受容体が発現されたt細胞
|
CA2994829A1
(en)
|
2015-08-07 |
2017-02-16 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Bispecific car t-cells for solid tumor targeting
|
EP3331913A1
(en)
|
2015-08-07 |
2018-06-13 |
Novartis AG |
Treatment of cancer using chimeric cd3 receptor proteins
|
JP6905163B2
(ja)
|
2015-09-03 |
2021-07-21 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
サイトカイン放出症候群を予測するバイオマーカー
|
EP3858388A1
(en)
|
2015-09-28 |
2021-08-04 |
Regents of the University of Minnesota |
Chimeric antigen receptor (car) t cells as therapeutic interventions for auto- and allo-immunity
|
DK3359660T3
(en)
|
2015-10-05 |
2020-02-17 |
Prec Biosciences Inc |
Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene
|
JP6816133B2
(ja)
|
2015-10-05 |
2021-01-20 |
プレシジョン バイオサイエンシズ,インク. |
改変ヒトt細胞受容体アルファ定常領域遺伝子を含む遺伝子改変細胞
|
US11230577B2
(en)
*
|
2015-10-13 |
2022-01-25 |
City Of Hope |
Chimeric antigen receptors containing a chlorotoxin domain
|
EP3370743A4
(en)
*
|
2015-11-05 |
2019-04-24 |
City of Hope |
METHODS OF PREPARING LYMPHOCYTES FOR ADOPTIVE TRANSFER THERAPY OF T-CELLS
|
US11020429B2
(en)
|
2015-11-05 |
2021-06-01 |
Juno Therapeutics, Inc. |
Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy
|
MA44314A
(fr)
|
2015-11-05 |
2018-09-12 |
Juno Therapeutics Inc |
Récepteurs chimériques contenant des domaines induisant traf, et compositions et méthodes associées
|
AU2016363025B2
(en)
|
2015-12-03 |
2021-04-08 |
Juno Therapeutics, Inc. |
Modified chimeric receptors and related compositions and methods
|
MA43378A
(fr)
|
2015-12-03 |
2018-10-10 |
Juno Therapeutics Inc |
Compositions et méthodes pour la reduction de la réponse immunitaire contre récepteurs d'antigène chimériques
|
MA43377A
(fr)
|
2015-12-04 |
2021-05-19 |
Hutchinson Fred Cancer Res |
Méthodes et compositions liées à la toxicité associée à la thérapie cellulaire
|
US11479755B2
(en)
|
2015-12-07 |
2022-10-25 |
2Seventy Bio, Inc. |
T cell compositions
|
JP7082055B2
(ja)
|
2015-12-22 |
2022-06-07 |
ノバルティス アーゲー |
抗癌治療における組み合わせ使用のためのメソテリンキメラ抗原受容体(car)およびpd-l1阻害剤に対する抗体
|
AU2017213661B2
(en)
*
|
2016-02-05 |
2022-06-02 |
City Of Hope |
Administration of engineered T cells for treatment of cancers in the central nervous system
|
EP3430548A1
(en)
|
2016-03-16 |
2019-01-23 |
Juno Therapeutics, Inc. |
Methods for determining dosing of a therapeutic agent and related treatments
|
EP3430549A1
(en)
|
2016-03-16 |
2019-01-23 |
Juno Therapeutics, Inc. |
Methods for adaptive design of a treatment regimen and related treatments
|
KR102366611B1
(ko)
|
2016-03-18 |
2022-02-23 |
프레드 헛친슨 켄서 리서치 센터 |
Cd20 면역요법을 위한 조성물 및 방법
|
EP4015536A1
(en)
|
2016-03-22 |
2022-06-22 |
Seattle Children's Hospital (DBA Seattle Children's Research Institute) |
Early intervention methods to prevent or ameliorate toxicity
|
WO2017165683A1
(en)
|
2016-03-23 |
2017-09-28 |
Novartis Ag |
Cell secreted minibodies and uses thereof
|
ES2937699T3
(es)
|
2016-04-22 |
2023-03-30 |
Crage Medical Co Ltd |
Composiciones y métodos de inmunoterapia celular
|
SI3455261T1
(sl)
|
2016-05-13 |
2023-01-31 |
Bioatla, Inc. |
Protitelesa proti ROR2, fragmenti protitelesa, njihovi imunokonjugati in uporabe le-teh
|
CA3026453A1
(en)
|
2016-06-03 |
2017-12-07 |
Memorial Sloan-Kettering Cancer Center |
Adoptive cell therapies as early treatment options
|
MA45341A
(fr)
|
2016-06-06 |
2019-04-10 |
Hutchinson Fred Cancer Res |
Procédés de traitement de malignités de lymphocytes b au moyen d'une thérapie cellulaire adoptive
|
CA3027103A1
(en)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Anti-b7-h3 antibodies and antibody drug conjugates
|
WO2017214335A1
(en)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Anti-b7-h3 antibodies and antibody drug conjugates
|
CN109563167A
(zh)
|
2016-06-08 |
2019-04-02 |
艾伯维公司 |
抗b7-h3抗体和抗体药物偶联物
|
EP3468599A2
(en)
|
2016-06-08 |
2019-04-17 |
AbbVie Inc. |
Anti-cd98 antibodies and antibody drug conjugates
|
WO2017214456A1
(en)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Anti-cd98 antibodies and antibody drug conjugates
|
CN109562170B
(zh)
|
2016-06-08 |
2023-01-13 |
艾伯维公司 |
抗cd98抗体及抗体药物偶联物
|
CA3028002A1
(en)
|
2016-06-27 |
2018-01-04 |
Juno Therapeutics, Inc. |
Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
|
MA45491A
(fr)
|
2016-06-27 |
2019-05-01 |
Juno Therapeutics Inc |
Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
|
CN110088133B
(zh)
|
2016-07-29 |
2023-12-08 |
朱诺治疗学股份有限公司 |
抗独特型抗体及相关方法
|
CA3032498A1
(en)
|
2016-08-02 |
2018-02-08 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
CN107793481A
(zh)
*
|
2016-08-31 |
2018-03-13 |
南京传奇生物科技有限公司 |
一种靶向人cd123的嵌合受体配体及其应用
|
WO2018058002A1
(en)
|
2016-09-23 |
2018-03-29 |
Fred Hutchinson Cancer Research Center |
Tcrs specific for minor histocompatibility (h) antigen ha-1 and uses thereof
|
EP3518943A4
(en)
|
2016-09-28 |
2020-04-22 |
Atossa Therapeutics, Inc. |
METHOD FOR ADAPTIVE CELL THERAPY
|
IL302917A
(en)
|
2016-10-07 |
2023-07-01 |
Tcr2 Therapeutics Inc |
Preparations and methods for reprogramming T-cell receptors using fusion proteins
|
AR110676A1
(es)
|
2016-10-07 |
2019-04-24 |
Novartis Ag |
Tratamiento del cáncer utilizando receptores de antígenos quiméricos
|
US11896615B2
(en)
|
2016-10-13 |
2024-02-13 |
Juno Therapeutics, Inc. |
Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
|
GB2573406B
(en)
|
2016-10-18 |
2021-11-10 |
Univ Minnesota |
Tumor infiltrating lymphocytes and methods of therapy
|
CA3041284A1
(en)
|
2016-10-20 |
2018-04-26 |
Celgene Corporation |
Cereblon-based heterodimerizable chimeric antigen receptors
|
WO2018085731A2
(en)
|
2016-11-03 |
2018-05-11 |
Juno Therapeutics, Inc. |
Combination therapy of a t cell therapy and a btk inhibitor
|
US20190292246A1
(en)
|
2016-11-03 |
2019-09-26 |
Juno Therapeutics, Inc. |
Combination therapy of a cell based therapy and a microglia imhibitor
|
EP3544996A2
(en)
|
2016-11-22 |
2019-10-02 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
BR112019010470A2
(pt)
|
2016-11-23 |
2019-09-10 |
Novartis Ag |
métodos de realce de resposta imune com everolimo, dactolisib ou ambos
|
AU2017368320A1
(en)
*
|
2016-12-02 |
2019-05-02 |
Cartesian Therapeutics, Inc. |
Cancer immuno therapy with highly enriched CD8+ chimeric antigen receptor T cells
|
CN110494565A
(zh)
|
2016-12-02 |
2019-11-22 |
朱诺治疗学股份有限公司 |
工程化b细胞及相关组合物和方法
|
MA46995A
(fr)
|
2016-12-03 |
2019-10-09 |
Acerta Pharma Bv |
Méthodes et compositions pour l'utilisation de lymphocytes t thérapeutiques en association avec des inhibiteurs de kinase
|
CA3045508A1
(en)
|
2016-12-03 |
2018-06-07 |
Juno Therapeutics, Inc. |
Methods for modulation of car-t cells
|
US20200078400A1
(en)
|
2016-12-03 |
2020-03-12 |
Juno Therapeutics, Inc. |
Methods for determining car-t cells dosing
|
KR102618373B1
(ko)
*
|
2016-12-09 |
2023-12-29 |
유에이비 리서치 파운데이션 |
키메라성 클로로톡신 수용체
|
US11408005B2
(en)
|
2016-12-12 |
2022-08-09 |
Seattle Children's Hospital |
Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells
|
AU2018207305A1
(en)
|
2017-01-10 |
2019-07-25 |
Juno Therapeutics, Inc. |
Epigenetic analysis of cell therapy and related methods
|
EP3579870A4
(en)
|
2017-02-07 |
2020-12-30 |
Seattle Children's Hospital (DBA Seattle Children's Research Institute) |
PHOSPHOLIPID ETHER (PLE) T CAR-LYMPHOCYTE TUMOR (CTCT) TARGETING AGENTS
|
CA3052779A1
(en)
|
2017-02-17 |
2018-08-23 |
Fred Hutchinson Cancer Research Center |
Combination therapies for treatment of bcma-related cancers and autoimmune disorders
|
BR112019017767A2
(pt)
|
2017-02-27 |
2020-04-07 |
Juno Therapeutics Inc |
composições, artigos de fabricação e métodos relacionados à dosagem em terapia celular
|
US11850262B2
(en)
|
2017-02-28 |
2023-12-26 |
Purdue Research Foundation |
Compositions and methods for CAR T cell therapy
|
AU2018234640B2
(en)
|
2017-03-14 |
2024-03-14 |
Juno Therapeutics, Inc. |
Methods for cryogenic storage
|
EP3595708A4
(en)
|
2017-03-15 |
2020-12-16 |
Fred Hutchinson Cancer Research Center |
HIGHLY POTENTIAL MAGE-A1 SPECIFIC TCRS AND USES
|
KR20190130608A
(ko)
|
2017-03-22 |
2019-11-22 |
노파르티스 아게 |
면역종양학을 위한 조성물 및 방법
|
CA3056439A1
(en)
|
2017-03-27 |
2018-10-04 |
National University Of Singapore |
Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy
|
EP3601537A4
(en)
|
2017-03-27 |
2021-01-13 |
National University of Singapore |
STIMULATING CELL LINES FOR EX VIVO EXPANSION AND ACTIVATION OF NATURAL KILLER CELLS
|
AU2018251188A1
(en)
|
2017-04-14 |
2019-10-31 |
Juno Therapeutics, Inc. |
Methods for assessing cell surface glycosylation
|
EP3612210A4
(en)
|
2017-04-19 |
2021-01-27 |
Board Of Regents, The University Of Texas System |
IMMUNE CELLS EXPRESSING MODIFIED ANTIGEN RECEPTORS
|
CA3061945A1
(en)
|
2017-05-01 |
2018-11-08 |
Juno Therapeutics, Inc. |
Combination of a cell therapy and an immunomodulatory compound
|
WO2018218072A1
(en)
|
2017-05-24 |
2018-11-29 |
Effector Therapeutics, Inc. |
Compositions and methods for an improved antitumor immune response
|
CA3064000A1
(en)
|
2017-05-24 |
2018-11-29 |
Effector Therapeutics, Inc. |
Methods and compositions for cellular immunotherapy
|
WO2018223101A1
(en)
|
2017-06-02 |
2018-12-06 |
Juno Therapeutics, Inc. |
Articles of manufacture and methods for treatment using adoptive cell therapy
|
JP2020526194A
(ja)
|
2017-06-29 |
2020-08-31 |
ジュノー セラピューティクス インコーポレイテッド |
免疫療法薬と関連する毒性を評価するためのマウスモデル
|
EP3645021A4
(en)
|
2017-06-30 |
2021-04-21 |
Intima Bioscience, Inc. |
ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
|
JP2020529834A
(ja)
|
2017-06-30 |
2020-10-15 |
プレシジョン バイオサイエンシズ,インク. |
T細胞受容体アルファ遺伝子の改変されたイントロンを含む遺伝子改変t細胞
|
US20220233588A1
(en)
|
2017-06-30 |
2022-07-28 |
Cellectis |
Cellular immunotherapy for repetitive administration
|
MA50057A
(fr)
|
2017-09-01 |
2020-07-08 |
Juno Therapeutics Inc |
Expression génique et évaluation d'un risque de développement d'une toxicité suite à une thérapie cellulaire
|
AU2018327229A1
(en)
|
2017-09-06 |
2020-02-27 |
Fred Hutchinson Cancer Center |
Strep-tag specific binding proteins and uses thereof
|
CA3071661A1
(en)
|
2017-09-06 |
2019-03-14 |
Fred Hutchinson Cancer Research Center |
Strep-tag specific chimeric receptors and uses thereof
|
WO2019051135A1
(en)
|
2017-09-06 |
2019-03-14 |
Fred Hutchinson Cancer Research Center |
METHODS FOR IMPROVING ADOPTIVE CELL THERAPY
|
AU2018341227A1
(en)
*
|
2017-09-27 |
2020-04-09 |
Ohio State Innovation Foundation |
Tissue factor-targeting CAR-NK and CAR-T cell therapy
|
US20210069241A1
(en)
|
2017-10-20 |
2021-03-11 |
Fred Hutchinson Cancer Research Center |
Compositions and methods of immunotherapy targeting tigit and/or cd112r or comprising cd226 overexpression
|
WO2019089858A2
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Methods of assessing or monitoring a response to a cell therapy
|
MA50855A
(fr)
|
2017-11-01 |
2020-09-09 |
Juno Therapeutics Inc |
Procédé de génération de compositions thérapeutiques de cellules modifiées
|
SG11202003657VA
(en)
|
2017-11-01 |
2020-05-28 |
Juno Therapeutics Inc |
Process for producing a t cell composition
|
WO2019089848A1
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Methods associated with tumor burden for assessing response to a cell therapy
|
WO2019090364A1
(en)
|
2017-11-06 |
2019-05-09 |
Juno Therapeutics, Inc. |
Combination of a cell therapy and a gamma secretase inhibitor
|
AU2018365080A1
(en)
*
|
2017-11-10 |
2020-05-07 |
Jura Bio, Inc. |
Major histocompatibility complex-based chimeric receptors and uses thereof for treating autoimmune diseases
|
JP2019088676A
(ja)
*
|
2017-11-16 |
2019-06-13 |
株式会社大一商会 |
遊技機
|
JP2019088674A
(ja)
*
|
2017-11-16 |
2019-06-13 |
株式会社大一商会 |
遊技機
|
EP3713584A1
(en)
*
|
2017-11-20 |
2020-09-30 |
Prospect Chartercare RWMC LLC D/B/A Roger Williams Medical Center |
Compositions for improving car-t cell functionality and use thereof
|
US20220267403A1
(en)
|
2017-12-01 |
2022-08-25 |
Fred Hutchinson Cancer Research Center |
Binding proteins specific for 5t4 and uses thereof
|
CN111989106A
(zh)
|
2017-12-01 |
2020-11-24 |
朱诺治疗学股份有限公司 |
基因工程化细胞的给药和调节方法
|
BR112020011144A2
(pt)
|
2017-12-08 |
2020-11-17 |
Juno Therapeutics Inc |
formulação de meio livre de soro para o cultivo de células e métodos de uso da mesma
|
MX2020005908A
(es)
|
2017-12-08 |
2020-10-07 |
Juno Therapeutics Inc |
Proceso para producir una composicion de celulas t modificadas.
|
WO2019140278A1
(en)
|
2018-01-11 |
2019-07-18 |
Fred Hutchinson Cancer Research Center |
Immunotherapy targeting core binding factor antigens
|
TW201940182A
(zh)
|
2018-01-22 |
2019-10-16 |
美商安德賽特公司 |
Car t 細胞之使用方法
|
US10596165B2
(en)
|
2018-02-12 |
2020-03-24 |
resTORbio, Inc. |
Combination therapies
|
WO2019157533A1
(en)
*
|
2018-02-12 |
2019-08-15 |
The General Hospital Corporation |
Chimeric antigen receptors targeting the tumor microenvironment
|
WO2019170845A1
(en)
|
2018-03-09 |
2019-09-12 |
Ospedale San Raffaele S.R.L. |
Il-1 antagonist and toxicity induced by cell therapy
|
EP3765487A4
(en)
*
|
2018-03-14 |
2022-01-05 |
Seattle Children's Hospital (DBA Seattle Children's Research Institute) |
ZETAKINE-DIRECTED T-LYMPHOCYTE IMMUNOTHERAPY, TARGETING THE IL-13 ALPHA 2 RECEPTOR
|
WO2019200122A1
(en)
|
2018-04-12 |
2019-10-17 |
Precision Biosciences, Inc. |
Optimized engineered nucleases having specificity for the human t cell receptor alpha constant region gene
|
US20210223248A1
(en)
|
2018-06-01 |
2021-07-22 |
Fred Hutchinson Cancer Research Center |
Biomarkers, uses thereof for selecting immunotherapy intervention, and immunotherapy methods
|
WO2019241426A1
(en)
|
2018-06-13 |
2019-12-19 |
Novartis Ag |
Bcma chimeric antigen receptors and uses thereof
|
CN110615842B
(zh)
*
|
2018-06-20 |
2023-05-09 |
上海隆耀生物科技有限公司 |
一种包含共刺激受体的嵌合抗原受体及应用
|
WO2020018964A1
(en)
|
2018-07-20 |
2020-01-23 |
Fred Hutchinson Cancer Research Center |
Compositions and methods for controlled expression of antigen-specific receptors
|
US20210230671A1
(en)
|
2018-08-09 |
2021-07-29 |
Juno Therapeutics, Inc. |
Methods for assessing integrated nucleic acids
|
CA3110905A1
(en)
|
2018-08-31 |
2020-03-05 |
Invectys SA |
Chimeric antigen receptors against multiple hla-g isoforms
|
WO2020068702A1
(en)
|
2018-09-24 |
2020-04-02 |
Fred Hutchinson Cancer Research Center |
Chimeric receptor proteins and uses thereof
|
NL2021789B1
(en)
|
2018-10-10 |
2020-05-14 |
Academisch Ziekenhuis Leiden |
Binding proteins specific for HA-1H and uses thereof
|
BR112021008133A2
(pt)
|
2018-10-31 |
2021-10-05 |
Juno Therapeutics Gmbh |
Métodos para seleção e estimulação de células e aparelhos para os mesmos
|
EP3877054B1
(en)
|
2018-11-06 |
2023-11-01 |
Juno Therapeutics, Inc. |
Process for producing genetically engineered t cells
|
AU2019377854A1
(en)
|
2018-11-08 |
2021-05-27 |
Juno Therapeutics, Inc. |
Methods and combinations for treatment and T cell modulation
|
JP2022513062A
(ja)
|
2018-11-16 |
2022-02-07 |
ジュノー セラピューティクス インコーポレイテッド |
B細胞悪性腫瘍を処置するために、操作されたt細胞を投薬する方法
|
MX2021006244A
(es)
|
2018-11-30 |
2021-09-10 |
Juno Therapeutics Inc |
Metodos de dosificacion y tratamiento de canceres de celulas b en terapia celular adoptiva.
|
JP2022513685A
(ja)
|
2018-11-30 |
2022-02-09 |
ジュノー セラピューティクス インコーポレイテッド |
養子細胞療法を用いた処置のための方法
|
PT3898946T
(pt)
|
2018-12-19 |
2023-05-09 |
Inst Curie |
Células t invariantes associadas a mucosa (mait) que expressam recetores de antigénio quiméricos
|
JP2022521513A
(ja)
|
2019-02-20 |
2022-04-08 |
フレッド ハッチンソン キャンサー リサーチ センター |
Rasネオ抗原に特異的な結合タンパク質およびその使用
|
EP3773918A4
(en)
|
2019-03-05 |
2022-01-05 |
Nkarta, Inc. |
CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY
|
AU2020287882A1
(en)
|
2019-06-07 |
2022-01-20 |
Juno Therapeutics, Inc. |
Automated T cell culture
|
US20220249637A1
(en)
|
2019-06-12 |
2022-08-11 |
Juno Therapeutics, Inc. |
Combination therapy of a cell-mediated cytotoxic therapy and an inhibitor of a prosurvival bcl2 family protein
|
WO2021035194A1
(en)
|
2019-08-22 |
2021-02-25 |
Juno Therapeutics, Inc. |
Combination therapy of a t cell therapy and an enhancer of zeste homolog 2 (ezh2) inhibitor and related methods
|
BR112022008023A2
(pt)
|
2019-10-30 |
2022-07-12 |
Juno Therapeutics Gmbh |
Dispositivos de seleção e/ou estimulação de células e métodos de uso
|
WO2021113780A1
(en)
|
2019-12-06 |
2021-06-10 |
Juno Therapeutics, Inc. |
Anti-idiotypic antibodies to gprc5d-targeted binding domains and related compositions and methods
|
JP2023504740A
(ja)
|
2019-12-06 |
2023-02-06 |
ジュノー セラピューティクス インコーポレイテッド |
Bcma標的結合ドメインに対する抗イディオタイプ抗体ならびに関連する組成物および方法
|
JP2023504737A
(ja)
|
2019-12-06 |
2023-02-06 |
ジュノー セラピューティクス インコーポレイテッド |
B細胞性悪性疾患を処置するための細胞療法と関連する毒性および奏効に関係する方法
|
MX2022008648A
(es)
|
2020-01-23 |
2022-12-15 |
The Children´S Medical Center Corp |
Diferenciacion de celulas t sin estroma a partir de celulas madre pluripotentes humanas.
|
JP2023512250A
(ja)
*
|
2020-01-31 |
2023-03-24 |
シティ・オブ・ホープ |
IL13Rα2陽性悪性腫瘍の治療のための標的キメラ抗原受容体修飾T細胞
|
WO2021173674A1
(en)
|
2020-02-26 |
2021-09-02 |
A2 Biotherapeutics, Inc. |
Polypeptides targeting mage-a3 peptide-mhc complexes and methods of use thereof
|
CA3175123A1
(en)
*
|
2020-03-12 |
2021-09-16 |
City Of Hope |
Targeted chimeric antigen receptor modified t cells for treatment of il13r.alpha.2 positive malignancies
|
EP4142723A2
(en)
|
2020-04-28 |
2023-03-08 |
Juno Therapeutics, Inc. |
Combination of bcma-directed t cell therapy and an immunomodulatory compound
|
WO2021221783A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
|
JP2023528215A
(ja)
|
2020-05-13 |
2023-07-04 |
ジュノー セラピューティクス インコーポレイテッド |
臨床応答に関連する特徴量の特定方法およびその使用
|
KR20230022868A
(ko)
|
2020-05-13 |
2023-02-16 |
주노 쎄러퓨티크스 인코퍼레이티드 |
재조합 수용체를 발현하는 공여자-배치 세포의 제조 방법
|
KR102297396B1
(ko)
|
2020-07-29 |
2021-09-06 |
(주)티카로스 |
면역시냅스를 안정화시키는 키메라 항원 수용체(car) t 세포
|
EP4192868A1
(en)
|
2020-08-05 |
2023-06-14 |
Juno Therapeutics, Inc. |
Anti-idiotypic antibodies to ror1-targeted binding domains and related compositions and methods
|
WO2022066965A2
(en)
|
2020-09-24 |
2022-03-31 |
Fred Hutchinson Cancer Research Center |
Immunotherapy targeting sox2 antigens
|
WO2022066973A1
(en)
|
2020-09-24 |
2022-03-31 |
Fred Hutchinson Cancer Research Center |
Immunotherapy targeting pbk or oip5 antigens
|
NL2026614B1
(en)
|
2020-10-02 |
2022-06-03 |
Academisch Ziekenhuis Leiden |
T cell receptors directed against bob1 and uses thereof
|
WO2022076353A1
(en)
|
2020-10-06 |
2022-04-14 |
Fred Hutchinson Cancer Research Center |
Compositions and methods for treating mage-a1-expressing disease
|
EP4247850A1
(en)
|
2020-11-20 |
2023-09-27 |
Simcere Innovation, Inc. |
Armed dual car-t compositions and methods for cancer immunotherapy
|
AU2021397206A1
(en)
*
|
2020-12-08 |
2023-07-27 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Anti-egfr chimeric antigen receptors
|
JP2023553157A
(ja)
|
2020-12-10 |
2023-12-20 |
ユーティレックス カンパニー リミテッド |
抗-pd-1抗体およびその用途
|
WO2022133030A1
(en)
|
2020-12-16 |
2022-06-23 |
Juno Therapeutics, Inc. |
Combination therapy of a cell therapy and a bcl2 inhibitor
|
CN114716548A
(zh)
|
2021-01-05 |
2022-07-08 |
(株)爱恩德生物 |
抗-fgfr3抗体及其用途
|
KR20230151513A
(ko)
|
2021-01-11 |
2023-11-01 |
사나 바이오테크놀로지, 인크. |
Cd8 표적 바이러스 벡터의 용도
|
UY39610A
(es)
|
2021-01-20 |
2022-08-31 |
Abbvie Inc |
Conjugados anticuerpo-fármaco anti-egfr
|
CN117693508A
(zh)
|
2021-03-03 |
2024-03-12 |
朱诺治疗学股份有限公司 |
T细胞疗法和dgk抑制剂的组合
|
JPWO2022196719A1
(pl)
|
2021-03-17 |
2022-09-22 |
|
|
KR20230159851A
(ko)
|
2021-03-22 |
2023-11-22 |
주노 쎄러퓨티크스 인코퍼레이티드 |
치료 세포 조성물의 효력을 결정하는 방법
|
WO2022212400A1
(en)
|
2021-03-29 |
2022-10-06 |
Juno Therapeutics, Inc. |
Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy
|
WO2022221737A1
(en)
|
2021-04-16 |
2022-10-20 |
Juno Therapeutics, Inc. |
T cell therapy in patients who have had prior stem cell transplant
|
KR20230171468A
(ko)
|
2021-04-16 |
2023-12-20 |
셀진 코포레이션 |
Bcma-지시된 t 세포 요법과의 조합 요법
|
JP2024517863A
(ja)
|
2021-05-06 |
2024-04-23 |
ジュノ・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
細胞を刺激し、形質導入する方法
|
WO2023288281A2
(en)
|
2021-07-15 |
2023-01-19 |
Fred Hutchinson Cancer Center |
Chimeric polypeptides
|
WO2023000036A1
(en)
*
|
2021-07-22 |
2023-01-26 |
The Westmead Institute for Medical Research |
Chimeric antigen receptor useful in treating cancer
|
TW202321457A
(zh)
|
2021-08-04 |
2023-06-01 |
美商薩那生物科技公司 |
靶向cd4之病毒載體之用途
|
WO2023023491A1
(en)
|
2021-08-16 |
2023-02-23 |
Hemogenyx Pharmaceuticals Llc |
Anti-flt3 antibodies, cars, car t cells and methods of use
|
WO2023081735A1
(en)
|
2021-11-03 |
2023-05-11 |
Celgene Corporation |
Chimeric antigen receptors specific for b-cell maturation antigen for use in treating myeloma
|
WO2023081715A1
(en)
|
2021-11-03 |
2023-05-11 |
Viracta Therapeutics, Inc. |
Combination of car t-cell therapy with btk inhibitors and methods of use thereof
|
EP4176895A1
(en)
*
|
2021-11-08 |
2023-05-10 |
AvenCell Europe GmbH |
Targeting modules against il13ra2 or her2 for use in combination with a chimeric antigen receptor
|
TW202342757A
(zh)
|
2021-12-17 |
2023-11-01 |
美商薩那生物科技公司 |
經修飾副黏液病毒科附著醣蛋白
|
WO2023115039A2
(en)
|
2021-12-17 |
2023-06-22 |
Sana Biotechnology, Inc. |
Modified paramyxoviridae fusion glycoproteins
|
WO2023150518A1
(en)
|
2022-02-01 |
2023-08-10 |
Sana Biotechnology, Inc. |
Cd3-targeted lentiviral vectors and uses thereof
|
NL2030990B1
(en)
|
2022-02-17 |
2023-09-01 |
Academisch Ziekenhuis Leiden |
T cell receptors directed against jchain and uses thereof
|
WO2023156587A1
(en)
|
2022-02-18 |
2023-08-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of tcr-deficient car-tregs in combination with anti-tcr complex monoclonal antibodies for inducing durable tolerance
|
NL2031118B1
(en)
|
2022-03-01 |
2023-09-07 |
Academisch Ziekenhuis Leiden |
T cell receptors directed against transcription factor wt1 and uses thereof
|
WO2023193015A1
(en)
|
2022-04-01 |
2023-10-05 |
Sana Biotechnology, Inc. |
Cytokine receptor agonist and viral vector combination therapies
|
WO2023215725A1
(en)
|
2022-05-02 |
2023-11-09 |
Fred Hutchinson Cancer Center |
Compositions and methods for cellular immunotherapy
|
WO2023213969A1
(en)
|
2022-05-05 |
2023-11-09 |
Juno Therapeutics Gmbh |
Viral-binding protein and related reagents, articles, and methods of use
|
WO2023220655A1
(en)
|
2022-05-11 |
2023-11-16 |
Celgene Corporation |
Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
|
WO2023220641A2
(en)
|
2022-05-11 |
2023-11-16 |
Juno Therapeutics, Inc. |
Methods and uses related to t cell therapy and production of same
|
WO2023230581A1
(en)
|
2022-05-25 |
2023-11-30 |
Celgene Corporation |
Methods of manufacturing t cell therapies
|
WO2023230548A1
(en)
|
2022-05-25 |
2023-11-30 |
Celgene Corporation |
Method for predicting response to a t cell therapy
|
WO2023237663A1
(en)
|
2022-06-09 |
2023-12-14 |
Institut National de la Santé et de la Recherche Médicale |
Use of the f359l missense irf4 variant for increasing the stability of regulatory t cells
|
NL2032130B1
(en)
|
2022-06-10 |
2023-12-18 |
Academisch Ziekenhuis Leiden |
T cell receptors directed against melanoma-associated antigen and uses thereof
|
WO2023250400A1
(en)
|
2022-06-22 |
2023-12-28 |
Juno Therapeutics, Inc. |
Treatment methods for second line therapy of cd19-targeted car t cells
|
WO2024047110A1
(en)
|
2022-08-31 |
2024-03-07 |
Institut National de la Santé et de la Recherche Médicale |
Method to generate more efficient car-t cells
|
WO2024054944A1
(en)
|
2022-09-08 |
2024-03-14 |
Juno Therapeutics, Inc. |
Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing
|
WO2024074713A1
(en)
|
2022-10-07 |
2024-04-11 |
Institut National de la Santé et de la Recherche Médicale |
Method to generate improving car-t cells
|
WO2024081820A1
(en)
|
2022-10-13 |
2024-04-18 |
Sana Biotechnology, Inc. |
Viral particles targeting hematopoietic stem cells
|